Guselkumab and IL-23 p19 Mechanism

What is the Guselkumab IL-23 binding p19 mechanism?

I'll pull up the structural and mechanistic literature on guselkumab's binding to the IL-23 p19 subunit.

Guselkumab's Mechanism of Action

Guselkumab is a fully human IgG1 monoclonal antibody that binds specifically to the p19 subunit of IL-23, blocking its interaction with the IL-23 receptor. Here's how the mechanism works at several levels:

p19 epitope binding

The p19 subunit is unique to IL-23 (unlike p40, which is shared with IL-12), so targeting p19 gives selectivity for IL-23 without affecting IL-12. Hydrogen-deuterium exchange studies characterize guselkumab's epitope on p19 as large — roughly 2,240 Ų of solvent-accessible surface area — and predominantly non-hydrophobic with a net-neutral surface charge. Critically, this epitope location sterically prevents IL-23 from engaging its receptor (IL-23R/IL-12Rβ1 complex), blocking downstream signaling. Binding affinity is in the picomolar range, and the antibody inhibits IL-23-induced STAT3 phosphorylation with an IC50 of approximately 0.2 nM in human PBMCs.

Downstream signaling consequences

When guselkumab blocks IL-23/receptor engagement, the JAK/STAT pathway (primarily JAK2–TYK2 activating STAT3) is not activated in responding lymphoid cells. This blunts the IL-23-driven differentiation and maintenance of Th17 cells, reducing downstream production of IL-17A, IL-17F, IL-22, and TNF — the effector cytokines responsible for tissue inflammation in psoriasis and psoriatic arthritis. Early clinical biopsy data confirmed that guselkumab treatment significantly reduces serum IL-17A and psoriasis gene expression at 12 weeks.

A mechanistic wrinkle: CD64-mediated enrichment at the source

More recent work (2022–2025) has revealed that guselkumab's native IgG1 Fc region allows it to bind CD64 (FcγRI), which is highly expressed on the IL-23-producing myeloid cells (macrophages, monocytes, dendritic cells) concentrated in lesional psoriatic tissue. This gives guselkumab something risankizumab lacks: guselkumab can anchor to CD64+ macrophages via its Fc domain while simultaneously capturing IL-23 secreted from those same cells. The guselkumab-IL-23 complex is then internalized and trafficked to low-pH lysosomal compartments, effectively removing IL-23 from the inflamed microenvironment at its source of production. In co-culture assays where IL-23 was produced endogenously by CD64+ cells rather than added exogenously, guselkumab showed roughly 10-fold greater potency than risankizumab for inhibiting IL-23 signaling — an Fc-dependent effect. CD64 binding does not trigger cytokine release from myeloid cells, so this mechanism appears to be a pure clearance mechanism rather than an activating one.

How this compares structurally to other p19 inhibitors

All three selective p19 blockers (guselkumab, risankizumab, tildrakizumab) bind distinct epitopes on p19, with only a 10-residue overlap region shared among them — and that shared region lies outside the IL-23 receptor-binding interface. Epitope size correlates strongly with binding affinity and clinical efficacy: guselkumab's large epitope surface area tracks with its clinical response rates, though risankizumab's even larger epitope (2,400 Ų) correlates with somewhat higher PASI-90 responses in that structural analysis.

These results are from an initial search, so the structural binding literature (particularly published crystallographic data for guselkumab itself, rather than hydrogen-deuterium exchange mapping) may be richer than what surfaced here.